Erythropoietin Mimetic Peptide Derivatives via PEGylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EPO mimetic peptides have limited clinical applications due to low biological activity and bioavailability, which restricts their effectiveness in treating disorders related to insufficient or defective red blood cell production.
Innovation Solution
Development of a novel EPO mimetic peptide derivative with improved biological activity and bioavailability, specifically designed to bind to the EPO receptor, along with its pharmaceutical salts, which are synthesized using solid-phase peptide synthesis and PEGylation, enhancing their stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current EPO mimetic peptides are used, then they can bind to EPO receptor and stimulate erythropoiesis, but their biological activity and bioavailability are low
Solution Approach 1:
The patent applies PEGylation technology to create a composite structure by conjugating polyethylene glycol chains to the EPO mimetic peptide. This composite material combines the biological activity of the peptide with the stability and extended circulation properties of PEG, thereby improving both biological activity and bioavailability simultaneously
Solution Approach 2:
The patent modifies the physical and chemical parameters of the EPO mimetic peptide through PEG conjugation, changing its molecular weight, hydrophilicity, and circulation half-life. These parameter changes enhance the peptide's bioavailability and biological activity without compromising its ability to bind to the EPO receptor
2Reliability
If EPO is used to treat renal anemia, then curative efficacy is almost 100%, but it does not improve renal function
Solution Approach 1:
The patent extracts and utilizes only the essential erythropoiesis-stimulating function of EPO by designing a mimetic peptide that specifically targets the EPO receptor. This extracted function provides high curative efficacy for anemia while avoiding the limitation of not improving renal function, as the peptide is designed solely for its hematopoietic effect
3Productivity
If recombinant human EPO is produced using gene recombinant technology, then it can be widely used in clinical, but the molecular structure is complex with high carbohydrate content
Solution Approach 1:
The patent extracts the essential amino acid sequence responsible for EPO's biological activity and removes the complex carbohydrate moieties. This extracted peptide structure maintains clinical availability and biological function while significantly reducing molecular structure complexity and glycosylation requirements
Solution Approach 2:
The patent creates a simplified copy of the EPO molecule by synthesizing a peptide that mimics the key functional regions of native EPO. This synthetic copy replicates the essential binding and signaling properties without requiring the complex full-length glycoprotein structure, enabling easier production and modification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The EPO mimetic peptide derivatives significantly stimulate erythropoiesis, as evidenced by increased peripheral blood reticulocyte counts, and extend the half-life of conjugates in the body, without affecting mature red blood cells, hemoglobin content, or white blood cell counts, demonstrating improved therapeutic potential for conditions like renal failure and anemia.
Implementation Method 1
bind to the EPO receptor and activate the EPO receptor or have the agonistic effect of EPO
Implementation Method 2
synthesized using solid-phase peptide synthesis and PEGylation, enhancing their stability and efficacy
Data Source
Figure 1~2
AI summary
What is provided is an EPO mimetic peptide derivatives defined as formula (I) and its pharmaceutical salt, the preparation thereof, wherein R1, R2, R3, R4, R5, n1, n2 are defined as described in description. A composition comprising of an EPO mimetic peptide derivatives defined as formula (I) and its pharmaceutical salt. The uses of the derivatives and its pharmaceutical salt, as well as the uses of the composition described above in treatment of diseases characterized by a deficiency of EPO or a low or defective red blood cell population. R1-R2-(CH2)n1-R3-(CH2)n2-R4-R5 (I)